61 A recent study has shed light on a significant advancement in the treatment of hepatocellular carcinoma (HCC), the most common type of primary liver cancer. The study, which was published in Nature Reviews Clinical Oncology, talks about the IMbrave 050 trial’s positive outcomes. This is a big step forward in using adjuvant immunotherapy to treat early-stage HCC. Hepatocellular carcinoma is a pressing global health issue, being the sixth most common cancer and the third leading cause of cancer-related deaths worldwide. Traditional treatments for early-stage HCC, such as surgical resection or local ablation, often result in a high recurrence rate, with up to 70% of patients experiencing a return of the disease within five years. The need for effective adjuvant therapies to prevent recurrence has been a long-standing challenge in the field of oncology. The IMbrave 050 trial was a phase III global study that looked at how well combining two immunotherapeutic drugs—atezolizumab and bevacizumab—worked as extra treatment for people with HCC who had already had surgery to remove the tumour or heat it up locally and were at a high risk of it coming back. Atezolizumab is an immune checkpoint inhibitor that targets the PD-L1 protein, thereby boosting the body’s immune response against cancer cells. Bevacizumab, on the other hand, is an anti-angiogenic agent that inhibits the formation of blood vessels that feed tumours, thus restricting their growth. The trial included 668 patients who were randomly assigned to receive either the combination therapy or to be placed under active surveillance. The results were compelling: the combination of atezolizumab and bevacizumab significantly improved recurrence-free survival (RFS) compared to active surveillance. At a median follow-up of 17.4 months, the study reported that the risk of disease recurrence was reduced by 28% in patients receiving the combination therapy, a statistically significant finding. One of the critical aspects of this study is its focus on patients who are at high risk of HCC recurrence. These patients were identified based on several criteria, including tumour size, the presence of microvascular invasion, and the degree of tumour differentiation. The ability to stratify patients based on their risk and tailor the treatment accordingly represents a more personalised approach to cancer care, which is increasingly being recognised as a vital component of effective cancer treatment. The study also highlighted the safety profile of the combination therapy. While there were higher incidences of adverse events in the treatment group compared to the active surveillance group, these were generally manageable. The most common side effects included elevated liver enzymes, rash, and hypothyroidism, which were mostly mild to moderate in severity. Importantly, the study reported that the benefits of reduced recurrence outweighed the risks associated with these side effects. This trial marks a significant shift in the landscape of HCC treatment. For decades, attempts to improve post-surgical outcomes in HCC with adjuvant therapies have largely been unsuccessful. Previous trials using various agents, such as sorafenib, retinoids, and interferons, failed to demonstrate a clear benefit in preventing recurrence. The success of the IMbrave 050 trial is therefore a landmark achievement, offering new hope for patients with early-stage HCC. In addition to its immediate clinical implications, the trial also sets the stage for further research into the role of immunotherapy in the perioperative setting. Combining neoadjuvant (before surgery) and adjuvant immunotherapies may be studied in the future. This could potentially boost the immune response against the tumour and lower the risk of recurrence even more. Moreover, the identification of biomarkers that predict response to immunotherapy could refine patient selection and improve outcomes even further. The results of the IMbrave 050 trial have already changed clinical practice. For example, atezolizumab and bevacizumab together are now recommended as a treatment for high-risk HCC patients who have had surgery or radiotherapy. This development not only underscores the potential of immunotherapy to change the course of HCC but also highlights the importance of continued innovation in cancer treatment.